Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas.

Competing Interests: Matthias A. Karajannis Stock and Other Ownership Interests: Johnson & Johnson (I) Consulting or Advisory Role: Bayer, Recursion Pharmaceuticals, QED Therapeutics, CereXis, AstraZeneca Research Funding: Novartis Travel, Accommodations, Expenses: Bayer, Debiopharm Group Uncompensated Relationships: Debiopharm Group Open Payments Link: https://openpaymentsdata.cms.gov/physician/710370/summary No other potential conflicts of interest were reported.Matthias A. Karajannis Stock and Other Ownership Interests: Johnson & Johnson (I) Consulting or Advisory Role: Bayer, Recursion Pharmaceuticals, QED Therapeutics, CereXis, AstraZeneca Research Funding: Novartis Travel, Accommodations, Expenses: Bayer, Debiopharm Group Uncompensated Relationships: Debiopharm Group Open Payments Link: https://openpaymentsdata.cms.gov/physician/710370/summary No other potential conflicts of interest were reported.